NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of “Hold” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have earned a consensus rating of “Hold” from the fifteen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $12.00.

A number of equities analysts recently weighed in on the stock. TD Cowen upped their price objective on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Cowen restated a “buy” rating on shares of NeoGenomics in a report on Wednesday. Leerink Partners set a $14.00 price target on NeoGenomics in a research report on Tuesday, October 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO opened at $12.83 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.62. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $17.75. The firm has a market capitalization of $1.66 billion, a PE ratio of -14.58 and a beta of 1.58. The business’s 50 day moving average price is $11.50 and its 200-day moving average price is $9.00.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The company had revenue of $187.80 million for the quarter, compared to analyst estimates of $183.85 million. During the same quarter last year, the firm posted $0.05 EPS. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. As a group, equities research analysts expect that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

Insider Activity at NeoGenomics

In other news, EVP Alicia C. Olivo sold 20,916 shares of NeoGenomics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares in the company, valued at $372,996. The trade was a 40.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NeoGenomics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd grew its stake in shares of NeoGenomics by 42.5% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after buying an additional 997 shares during the period. Moody National Bank Trust Division lifted its holdings in NeoGenomics by 1.4% in the third quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock valued at $698,000 after acquiring an additional 1,227 shares during the last quarter. Amalgamated Bank grew its position in NeoGenomics by 3.4% in the third quarter. Amalgamated Bank now owns 37,965 shares of the medical research company’s stock worth $293,000 after acquiring an additional 1,255 shares during the period. GAMMA Investing LLC increased its stake in NeoGenomics by 68.2% during the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after acquiring an additional 1,460 shares during the last quarter. Finally, Moors & Cabot Inc. raised its position in NeoGenomics by 14.6% in the third quarter. Moors & Cabot Inc. now owns 13,750 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 1,750 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.